




1 Supplementary

Serum level of estrone (E1) in mice implanted with MedRod realising different doses of E1




Estrone doses released by the MedRod implants

- 0,3 µg/d E1
- ▲ 0,6 µg/d E1
- 1,8 µg/d E1


2
3
4
5
6
7

Figure S1. Optimisation of the MedRod delivery using estrone as test compound. Serum levels of the estrogenic compound estrone (E1) measured by LC-MS/MS in athymic female mice implanted subcutaneously (s.c.) with MedRod releasing E1 at different doses, i.e., 0.3 µg/d (squares), 0.6 µg/d (triangles) or 1.8 µg/d (circles). Each line represents data from 5 mice. Data is expressed as mean ± SEM.


A. Orthotopic tumour induction procedure



B. Macroscopic appearance of mice at sacrifice, laparotomy and surgically removed tumour and the uterus




C. Macroscopic appearance and uterine histology of a placebo treated mouse (left) and an E2 treated mouse (right)



8
9
10
11
12
13
14
15
16

Figure S2. Overview of the tumour induction and characterisation. (a). Procedure of orthotopic tumour induction. One uterine horn is exteriorized and ipsilateral OVX was performed prior to cell injection. Cells resuspended in 30 μ l ice-cold Matrigel are then slowly injected through the myometrium, into the endometrial cavity with a 25G needle syringe. (b). Macroscopic appearance of mice, abdominal cavity at laparotomy and surgically resected uterus with tumour at the time of sacrifice. (c). Macroscopic appearance of uterus with tumour and histology (haematoxylin & eosin, H&E) of mouse endometrium receiving either placebo (no growth/atrophic endometrium) or E2 (with evident glandular growth).

Uterine and tumour weight in OVX mice implanted with MedRod realising the low-active estrone (E1; 0,3 µg/d)

17
18

Figure S3. Uterine and tumour weight using less-sustained estrogen signalling.

19 Since experiments were conducted with high E2 doses, uterine and tumour growth were tested
20 using pellets (MedRods) releasing the low active E1 at a dose as low as of 0.3 µg/day corresponding
21 to approximately 80nM of circulating E1 (see supplemental Figure 1). E1 requires concentrations of
22 at least 1-2 magnitudes higher than E2 to elicit similar responses [33]. Data shown in figure refers
23 to the wet weights at humane endpoint (animal sacrifice, six weeks after OVX). E1 was not
24 significantly converted to E2 (measured by LC-MS in these mice) but it induced strong uterine
25 responses and tumour growth that were not distinguishable from E2 treated mice.